In this issue: Knock on effects of the Valsartan recall, the future of...
AstraZeneca’s Farxiga reduces CV events in diabetes patients
AstraZeneca has reported positive data from pre-specified sub-analyses of its Farxiga (dapagliflozin) drug in the Phase III DECLARE-TIMI 58 clinical trial involving type-2 diabetes (T2D) patients with prior heart attack history.
Lilly’s Cyramza clears Phase III lung cancer trial
Eli Lilly has reported positive results from the Phase III RELAY clinical trial performed to evaluate Cyramza (ramucirumab) in metastatic non-small cell lung cancer (NSCLC) patients with activating EGFR mutations.
ViiV reports positive data for once-a-month HIV-1 therapy
ViiV Healthcare has reported positive data from two Phase III clinical trials studying cabotegravir and rilpivirine in adults living with human immunodeficiency virus type-1 (HIV-1).
Alnylam’s hepatic porphyria drug yields positive results in trial
Alnylam Pharmaceuticals has reported that the Phase III ENVISION clinical trial of givosiran has met its primary endpoint with reduction in the annualised rate of composite porphyria attacks compared to placebo in patients with acute hepatic porphyria.
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
Fleet Bioprocessing to Attend the RSC Sixth Analytical Biosciences ECRM19
Fleet Bioprocessing has announced that it will be attending the forthcoming RSC Sixth Analytical Biosciences Early Career Research Meeting (ECRM) at the University of Cambridge, UK.
AstraZeneca’s Lynparza meets primary endpoint in cancer trial
AstraZeneca and Merck have reported positive data from the Phase III POLO clinical trial of Lynparza (olaparib) as a first-line maintenance monotherapy in pancreatic cancer patients.
Boehringer closes enrolment in Phase IIa trial for NASH
Boehringer Ingelheim has completed enrolment of patients in a Phase IIa clinical trial for the assessment of BI 1467335 to treat nonalcoholic steatohepatitis (NASH).
ARCA biopharma to study Gencaro in Phase III trial
ARCA biopharma has announced plans to investigate Gencaro (bucindolol hydrochloride) as a genetically-targeted therapy in a pivotal Phase III clinical trial for atrial fibrillation (AF) in patients with a certain type of heart failure (HF).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.